Isis Pharmaceuticals (ISIS) 62.32 $ISIS
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 28.27 (-0.27), ISIS: 62.32 (+0.45), GLYC: 9.00 (+0.49), RGDO: 0.89 (+0.02)
Jim Cramer's Top Stock Picks: RH COST AGIO BLUE ISIS
at The Street - Thu Dec 11, 5:00AM CST
Restoration Hardware and Costco should benefit from lower oil prices, and the recent drop in Agios' and Bluebird Bio's shares means a buying opportunity, Cramer says.
BLUE: 91.28 (+5.16), RH: 93.59 (-0.40), ISIS: 62.32 (+0.45), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36)
High Triglyceridemia - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pnv28/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acasti Pharma - Actavis - Alnylam - Arisaph - Astellas Pharma - AstraZeneca - Cardax Pharmaceuticals - Catabasis Pharmaceuticals - Essentialis - Isis Pharmaceuticals - Novartis - Pharmena - Poxel - Tekmira Pharmaceuticals - Thetis Pharmaceuticals - Trygg Pharma For more information visit http://www.researchandmarkets.com/research/4pnv28/high
ACST: 0.54 (+0.06), ISIS: 62.32 (+0.45), TKMR: 14.28 (+0.19), NVS: 93.52 (-0.82)
Cramer's Mad Money - The Good Isis (12/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 11, 3:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 10. CEO Interview: Dr. Stanley Crooke, Isis Pharmaceuticals (NASDAQ: ISIS ) Isis Pharmaceuticals ( ISIS ) produces treatments that bind to...
BLUE: 91.28 (+5.16), TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), FRPT: 17.14 (-0.88), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), XLV: 68.78 (-1.07), RFMD: 15.50 (-0.29), NOV: 61.55 (-1.46), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), TQNT: 25.87 (-0.51), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36), VZ: 45.58 (-0.78), CSCO: 26.85 (-0.14)
Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices
at The Street - Wed Dec 10, 7:41PM CST
The negative effects of oil below $60 per barrel on certain companies could outweigh the gains seen from higher consumer spending, at least in the short term, Cramer says.
TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), F: 14.99 (-0.29), EMES: 44.67 (+0.92), BOKF: 58.67 (-1.75), FRPT: 17.14 (-0.88), BPT: 67.95 (-2.57), HBHC: 29.40 (-0.82), PBR: 7.11 (-0.31), T: 32.16 (-0.55), CFR: 70.00 (-1.62), SAVE: 68.12 (-0.88), JPM: 60.04 (-1.10), COST: 137.88 (-3.53), XLF: 24.14 (-0.48), BLUE: 91.28 (+5.16), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), CONN: 17.44 (+0.35), JCP: 6.38 (+0.29), GM: 31.57 (-0.62), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47)
Isis Pharmaceuticals (ISIS) Is Strong On High Volume Today
at The Street - Wed Dec 10, 9:13AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a strong on high relative volume candidate
ISIS: 62.32 (+0.45)
Hereditary Angioedema (HAE) - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/95nltr/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - BioCryst Pharmaceuticals - Cevec Pharmaceuticals - CSL - Dyax - Global Blood Therapeutics - iBio - Isis Pharmaceuticals - Pharming - Ra Pharmaceuticals - Shire For more information visit http://www.researchandmarkets.com/research/95nltr/hereditary
BCRX: 10.06 (+0.02), ISIS: 62.32 (+0.45), DYAX: 14.18 (-0.05)
ISIS Jumps on Positive Results for Venous Thrombosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 5:35PM CST
Shares of Isis Pharmaceuticals (ISIS) were up after the company announced encouraging results from a study on ISIS-FXIRx.
BIIB: 344.49 (+2.16), JNJ: 104.43 (-2.29), ISIS: 62.32 (+0.45)
SmarTrend Watching for Potential Pullback in Shares of Isis Pharmaceuticals After 1.75% Gain
Comtex SmarTrend(R) - Tue Dec 09, 4:35PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $55.25 to a high of $58.98. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $58.10 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 62.32 (+0.45)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NRCIA: 13.13 (-0.97), VCYT: 7.45 (+0.14), ISIS: 62.32 (+0.45), CBST: 96.31 (+0.04), AKAO: 11.91 (-0.31), CLDN: 17.25 (+0.75), PDCE: 33.13 (-0.89), MTEX: 28.10 (-1.00), NRCIB: 38.50 (-0.03)
The iShares Russell 2000 ETF: 3 Reasons to Buy
Selena Maranjian, The Motley Fool - Motley Fool - Tue Dec 09, 10:12AM CST
Small companies can deliver big rewards. Photo: Flickr user George Redgrave If you're interested in the stock market and want to invest in it, a good way to do so is with an exchange-traded fund (ETF) that's based on a broad index. A great one...
ISIS: 62.32 (+0.45), CAMP: 19.20 (-0.07), INVN: 15.18 (-0.29), IWM: 114.71 (-1.41)
Critical Alerts For Mobileye NV, bluebird bio Inc., Isis Pharmaceuticals, Castlight Health and ConocoPhillips Released By InvestorsObserver
PR Newswire - Tue Dec 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MBLY, BLUE, ISIS, CSLT and COP.
BLUE: 91.28 (+5.16), ISIS: 62.32 (+0.45), COP: 62.45 (-1.16), CSLT: 12.17 (-0.73), MBLY: 40.78 (-1.19)
Isis Pharmaceuticals Up 72.0% Since SmarTrend Uptrend Call (ISIS)
Comtex SmarTrend(R) - Mon Dec 08, 5:19PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 4 months, Isis Pharmaceuticals has returned 72.05% as of today's recent price of $56.99.
ISIS: 62.32 (+0.45)
Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
PR Newswire - Sun Dec 07, 1:05PM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data from its Phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events (VTE) in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXIRx is designed to reduce the production of Factor XI, a coagulation factor that plays a key role in thrombosis. These data were published in The New England Journal of Medicine and will be presented at the 56th American Society of Hematology meeting as a late-breaking oral presentation on Tuesday, December 9, 2014.
ISIS: 62.32 (+0.45)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), TEVA: 55.92 (-0.92), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), SNY: 45.16 (-1.05), FOLD: 8.15 (+0.18), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Gilead Sciences, Inc. Beats Another Threat
Brian Orelli, The Motley Fool - Motley Fool - Fri Dec 05, 7:30AM CST
A drug that brings in billions of dollars in its first year on the market -- that's billion s , with an s at the end -- is bound to draw a lot of interest. For Gilead Sciences , that interest comes in the form of other companies claiming patent...
ISIS: 62.32 (+0.45), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), ABBV: 65.27 (-1.76)
Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
PR Newswire - Fri Dec 05, 6:00AM CST
Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide. Dr. Crooke was selected for the lifetime achievement award by an independent panel of global life sciences experts, based on Dr. Crooke's dedication to advancing science and medicine as a physician, a scientist, a leader and as a successful entrepreneur. The lifetime achievement award recognizes Dr. Crooke's innovative spirit and his perseverance to stay focused on a lifetime goal of creating the drugs of the future. Dr. Crooke's accomplishments were recognized at the annual SCRIP awards ceremony held on December 3rd at The Lancaster Hotel in London.
ISIS: 62.32 (+0.45)
Earnings Estimates Moving Higher for Isis Pharmaceuticals (ISIS): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:51AM CST
Isis Pharmaceuticals has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.
ISIS: 62.32 (+0.45)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 62.32 (+0.45), OPK: 8.18 (-0.11), ISR: 1.62 (-0.02), FOLD: 8.15 (+0.18), NSPH: 0.36 (+0.02)
Why Isis Pharmaceuticals, Inc. Stock Leaped 12% in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 7:32AM CST
ISIS data by YCharts What: Shares of Isis Pharmaceuticals , a biopharmaceutical company focused on using its proprietary antisense technology platform to develop therapies across a wide range of disease implications, motored ahead by 12% in...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), AZN: 71.80 (-1.80)
Venous Thromboembolism - Pipeline Review, H2 2014
M2 - Fri Dec 12, 4:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/h48x9c/venous) has announced the addition of the "Venous Thromboembolism - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Venous Thromboembolism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Venous Thromboembolism and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Venous Thromboembolism - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Venous Thromboembolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - Isis Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Bayer AG - Portola Pharmaceuticals, Inc. - Green Cross Corporation - Regado Biosciences, Inc. - GlycoMimetics, Inc. - Gamma Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/h48x9c/venous
PTLA: 28.27 (-0.27), ISIS: 62.32 (+0.45), GLYC: 9.00 (+0.49), RGDO: 0.89 (+0.02)
Jim Cramer's Top Stock Picks: RH COST AGIO BLUE ISIS
at The Street - Thu Dec 11, 5:00AM CST
Restoration Hardware and Costco should benefit from lower oil prices, and the recent drop in Agios' and Bluebird Bio's shares means a buying opportunity, Cramer says.
BLUE: 91.28 (+5.16), RH: 93.59 (-0.40), ISIS: 62.32 (+0.45), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36)
High Triglyceridemia - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4pnv28/high) has announced the addition of the "High Triglyceridemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for High Triglyceridemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for High Triglyceridemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for High Triglyceridemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding High Triglyceridemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Acasti Pharma - Actavis - Alnylam - Arisaph - Astellas Pharma - AstraZeneca - Cardax Pharmaceuticals - Catabasis Pharmaceuticals - Essentialis - Isis Pharmaceuticals - Novartis - Pharmena - Poxel - Tekmira Pharmaceuticals - Thetis Pharmaceuticals - Trygg Pharma For more information visit http://www.researchandmarkets.com/research/4pnv28/high
ACST: 0.54 (+0.06), ISIS: 62.32 (+0.45), TKMR: 14.28 (+0.19), NVS: 93.52 (-0.82)
Cramer's Mad Money - The Good Isis (12/10/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Thu Dec 11, 3:43AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Wednesday December 10. CEO Interview: Dr. Stanley Crooke, Isis Pharmaceuticals (NASDAQ: ISIS ) Isis Pharmaceuticals ( ISIS ) produces treatments that bind to...
BLUE: 91.28 (+5.16), TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), FRPT: 17.14 (-0.88), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), XLV: 68.78 (-1.07), RFMD: 15.50 (-0.29), NOV: 61.55 (-1.46), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), TQNT: 25.87 (-0.51), COST: 137.88 (-3.53), AGIO: 119.56 (+0.36), VZ: 45.58 (-0.78), CSCO: 26.85 (-0.14)
Jim Cramer's 'Mad Money' Recap: The Good News-Bad News of Lower Oil Prices
at The Street - Wed Dec 10, 7:41PM CST
The negative effects of oil below $60 per barrel on certain companies could outweigh the gains seen from higher consumer spending, at least in the short term, Cramer says.
TSLA: 207.00 (-1.88), RH: 93.59 (-0.40), F: 14.99 (-0.29), EMES: 44.67 (+0.92), BOKF: 58.67 (-1.75), FRPT: 17.14 (-0.88), BPT: 67.95 (-2.57), HBHC: 29.40 (-0.82), PBR: 7.11 (-0.31), T: 32.16 (-0.55), CFR: 70.00 (-1.62), SAVE: 68.12 (-0.88), JPM: 60.04 (-1.10), COST: 137.88 (-3.53), XLF: 24.14 (-0.48), BLUE: 91.28 (+5.16), BA: 120.77 (-2.60), CELG: 114.49 (-2.25), ISIS: 62.32 (+0.45), KITE: 54.79 (+0.39), CONN: 17.44 (+0.35), JCP: 6.38 (+0.29), GM: 31.57 (-0.62), AGIO: 119.56 (+0.36), PAY: 33.01 (-1.47)
Isis Pharmaceuticals (ISIS) Is Strong On High Volume Today
at The Street - Wed Dec 10, 9:13AM CST
Trade-Ideas LLC identified Isis Pharmaceuticals (ISIS) as a strong on high relative volume candidate
ISIS: 62.32 (+0.45)
Hereditary Angioedema (HAE) - Pipeline Review, H2 2014
M2 - Wed Dec 10, 3:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/95nltr/hereditary) has announced the addition of the "Hereditary Angioedema (HAE) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hereditary Angioedema (HAE), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hereditary Angioedema (HAE) and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hereditary Angioedema (HAE) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hereditary Angioedema (HAE) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - BioCryst Pharmaceuticals - Cevec Pharmaceuticals - CSL - Dyax - Global Blood Therapeutics - iBio - Isis Pharmaceuticals - Pharming - Ra Pharmaceuticals - Shire For more information visit http://www.researchandmarkets.com/research/95nltr/hereditary
BCRX: 10.06 (+0.02), ISIS: 62.32 (+0.45), DYAX: 14.18 (-0.05)
ISIS Jumps on Positive Results for Venous Thrombosis Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 09, 5:35PM CST
Shares of Isis Pharmaceuticals (ISIS) were up after the company announced encouraging results from a study on ISIS-FXIRx.
BIIB: 344.49 (+2.16), JNJ: 104.43 (-2.29), ISIS: 62.32 (+0.45)
SmarTrend Watching for Potential Pullback in Shares of Isis Pharmaceuticals After 1.75% Gain
Comtex SmarTrend(R) - Tue Dec 09, 4:35PM CST
Isis Pharmaceuticals (NASDAQ:ISIS) traded in a range yesterday that spanned from a low of $55.25 to a high of $58.98. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $58.10 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ISIS: 62.32 (+0.45)
Nasdaq stocks posting largest percentage increases
AP - Tue Dec 09, 12:21PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
NRCIA: 13.13 (-0.97), VCYT: 7.45 (+0.14), ISIS: 62.32 (+0.45), CBST: 96.31 (+0.04), AKAO: 11.91 (-0.31), CLDN: 17.25 (+0.75), PDCE: 33.13 (-0.89), MTEX: 28.10 (-1.00), NRCIB: 38.50 (-0.03)
The iShares Russell 2000 ETF: 3 Reasons to Buy
Selena Maranjian, The Motley Fool - Motley Fool - Tue Dec 09, 10:12AM CST
Small companies can deliver big rewards. Photo: Flickr user George Redgrave If you're interested in the stock market and want to invest in it, a good way to do so is with an exchange-traded fund (ETF) that's based on a broad index. A great one...
ISIS: 62.32 (+0.45), CAMP: 19.20 (-0.07), INVN: 15.18 (-0.29), IWM: 114.71 (-1.41)
Critical Alerts For Mobileye NV, bluebird bio Inc., Isis Pharmaceuticals, Castlight Health and ConocoPhillips Released By InvestorsObserver
PR Newswire - Tue Dec 09, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for MBLY, BLUE, ISIS, CSLT and COP.
BLUE: 91.28 (+5.16), ISIS: 62.32 (+0.45), COP: 62.45 (-1.16), CSLT: 12.17 (-0.73), MBLY: 40.78 (-1.19)
Isis Pharmaceuticals Up 72.0% Since SmarTrend Uptrend Call (ISIS)
Comtex SmarTrend(R) - Mon Dec 08, 5:19PM CST
SmarTrend identified an Uptrend for Isis Pharmaceuticals (NASDAQ:ISIS) on August 7th, 2014 at $33.13. In approximately 4 months, Isis Pharmaceuticals has returned 72.05% as of today's recent price of $56.99.
ISIS: 62.32 (+0.45)
Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
PR Newswire - Sun Dec 07, 1:05PM CST
Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today final data from its Phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events (VTE) in patients treated with ISIS-FXIRx undergoing total knee replacement surgery, or total knee arthroplasty (TKA). ISIS-FXIRx is designed to reduce the production of Factor XI, a coagulation factor that plays a key role in thrombosis. These data were published in The New England Journal of Medicine and will be presented at the 56th American Society of Hematology meeting as a late-breaking oral presentation on Tuesday, December 9, 2014.
ISIS: 62.32 (+0.45)
3 Large Cap Biotech Stocks That Could Pay Dividends, But Won't
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 07, 11:39AM CST
Source: Flickr user Tax Credits Dividend paying companies are a key part of any investor's long-haul portfolio, but investors that lean toward high growth industries like biotechnology have few dividend-paying options. Despite multibillion...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), OMED: 19.77 (-0.42), GILD: 104.13 (-0.18), TEVA: 55.92 (-0.92), EPZM: 18.35 (-1.45), AGIO: 119.56 (+0.36), SNY: 45.16 (-1.05), FOLD: 8.15 (+0.18), XLRN: 41.77 (+0.29), NVS: 93.52 (-0.82), CELG: 114.49 (-2.25)
Gilead Sciences, Inc. Beats Another Threat
Brian Orelli, The Motley Fool - Motley Fool - Fri Dec 05, 7:30AM CST
A drug that brings in billions of dollars in its first year on the market -- that's billion s , with an s at the end -- is bound to draw a lot of interest. For Gilead Sciences , that interest comes in the form of other companies claiming patent...
ISIS: 62.32 (+0.45), GILD: 104.13 (-0.18), MRK: 57.72 (-1.62), ABBV: 65.27 (-1.76)
Isis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Prestigious SCRIP Lifetime Achievement Award
PR Newswire - Fri Dec 05, 6:00AM CST
Stanley T. Crooke, Ph.D., M.D., founder, CEO and chairman of the board of directors of Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), has been awarded the 2014 SCRIP Lifetime Achievement Award, one of the most prestigious of its kind in the pharmaceutical and biotechnology industries worldwide. Dr. Crooke was selected for the lifetime achievement award by an independent panel of global life sciences experts, based on Dr. Crooke's dedication to advancing science and medicine as a physician, a scientist, a leader and as a successful entrepreneur. The lifetime achievement award recognizes Dr. Crooke's innovative spirit and his perseverance to stay focused on a lifetime goal of creating the drugs of the future. Dr. Crooke's accomplishments were recognized at the annual SCRIP awards ceremony held on December 3rd at The Lancaster Hotel in London.
ISIS: 62.32 (+0.45)
Earnings Estimates Moving Higher for Isis Pharmaceuticals (ISIS): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 7:51AM CST
Isis Pharmaceuticals has decent short-term momentum and is seeing solid activity on the earnings estimate revision front as well.
ISIS: 62.32 (+0.45)
Biotech Stocks Technical Coverage - OPKO Health, IsoRay, Nanosphere, Amicus Therapeutics, and Isis Pharma
PR Newswire - Thu Dec 04, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: OPKO Health Inc. (NYSE: OPK), IsoRay Inc. (NYSE MKT: ISR), Nanosphere Inc. (NASDAQ: NSPH), Amicus Therapeutics Inc. (NASDAQ: FOLD), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Wednesday, December 03, 2014, the NASDAQ Composite ended at 4,774.47, up 0.39%, the Dow Jones Industrial Average advanced 0.18%, to finish the day at 17,912.62, and the S&P 500 closed at 2,074.33, up 0.38%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 812.13, up 0.15%, with the index also advancing 9.64% in the previous three months. Register for your complimentary reports on these five stocks at:
ISIS: 62.32 (+0.45), OPK: 8.18 (-0.11), ISR: 1.62 (-0.02), FOLD: 8.15 (+0.18), NSPH: 0.36 (+0.02)
Why Isis Pharmaceuticals, Inc. Stock Leaped 12% in November
Sean Williams, The Motley Fool - Motley Fool - Thu Dec 04, 7:32AM CST
ISIS data by YCharts What: Shares of Isis Pharmaceuticals , a biopharmaceutical company focused on using its proprietary antisense technology platform to develop therapies across a wide range of disease implications, motored ahead by 12% in...
BIIB: 344.49 (+2.16), ISIS: 62.32 (+0.45), AZN: 71.80 (-1.80)
